Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 5Unknown 3Completed 3Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 20Recurrence 5Leukemia, Myeloid, Acute 4Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Waldenstrom Macroglobulinemia 1Renal Insufficiency 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Hypergammaglobulinemia 1Hodgkin Disease 1Hematologic Diseases 1Disease 1Breast Neoplasms 1

Interventions

Melphalan 16Cyclophosphamide 14Dexamethasone 13fludarabine phosphate 12Filgrastim 11Antilymphocyte Serum 11fludarabine 8Radiotherapy 8Mycophenolic Acid 8Cyclosporine 8Busulfan 8Whole-Body Irradiation 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Methylprednisolone 6Lenalidomide 6Bortezomib 6pomalidomide 5Rituximab 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Flow Cytometry 4Etoposide 4Arsenic Trioxide 4liposomal doxorubicin 3Thalidomide 3Surveys and Questionnaires 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Plasma Cell × daratumumab × Clear all
NCT04614636 2023-09-21

FT538 in Subjects With Advanced Hematologic Malignancies

Fate Therapeutics

Phase 1 Terminated
42 enrolled
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡